Tumour progression is modulated by the local microenvironment. This environment is
populated by many immune cells, of which macrophages are among the most abundant …

Tumor-associated macrophages (TAMs) have multiple potent functions in cancer and, thus,
represent important therapeutic targets. These diverse functions highlight the heterogenous …

Neutrophils accumulate in solid tumors, and their abundance correlates with poor prognosis.
Neutrophils are not homogeneous, however, and could play different roles in cancer …

In recent years, tumor immunotherapy has made significant progress. However, tumor
immunotherapy, particularly immune checkpoint inhibitors (eg, PD-1/PD-L1 inhibitors) …

The metabolically hostile tumour microenvironment imposes barriers to tumour-infiltrating
immune cells and impedes durable clinical remission following immunotherapy. Metabolic …

Neutrophils are the most abundant myeloid cells in human blood and are emerging as
important regulators of cancer. However, their functional importance has often been …

Immunotherapy has revolutionized cancer treatment, but efficacy remains limited in most
clinical settings. Cancer is a systemic disease that induces many functional and …

Immune-checkpoint blockade (ICB) combined with neoadjuvant chemotherapy improves
pathological complete response in breast cancer. To understand why only a subset of …

The tumor microenvironment (TME) influences cancer progression and therapy response.
Therefore, understanding what regulates the TME immune compartment is vital. Here we …

Cancer immunotherapy offers substantive benefit to patients with various tumour types, in
some cases leading to complete tumour clearance. However, many patients do not respond …